• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Predictors of Development of Atrial Fibrillation in Patients With Embolic Stroke Of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial
Conclusions: Besides age as the most important variable, several other factors, including hypertension, higher body mass index, and lack of diabetes, are independent predictors of AF after ESUS. When baseline NT-proBNP was available, only older age and elevation of this biomarker were predictive of subsequent AF. Understanding who is at higher risk of developing AF will assist in identifying patients who may benefit from more intense, long-term cardiac monitoring.PMID:34649459 | DOI:10.1161/CIRCULATIONAHA.121.055176
Source: Circulation - October 15, 2021 Category: Cardiology Authors: Maria Cecilia Bahit Ralph L Sacco J Donald Easton Juliane Meyerhoff Lisa Cronin Eva Kleine Claudia Grauer Martina Brueckmann Hans-Christoph Diener Renato D Lopes Michael Brainin Philippe Lyrer Rolf Wachter Tomas Segura Christopher B Granger Source Type: research

Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source 　- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
CONCLUSIONS: Dabigatran was putatively associated with a lower relative risk of recurrent stroke compared with aspirin in Japanese ESUS patients. PMID: 33132228 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 30, 2020 Category: Cardiology Authors: Toyoda K, Uchiyama S, Hagihara Y, Kuwashiro T, Mori T, Kamiyama K, Urano Y, Taniguchi A, Nozaki K, Cronin L, Grauer C, Brueckmann M, Diener HC Tags: Circ J Source Type: research

Results from two Pradaxa trials to be presented at WSC
Results from Pradaxa ® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke CongressData from key trials will aid in increasing scientific understanding of ESUS and CVTRESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa ® vs ASA
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

Design of Randomized, double‐blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE‐SPECT ESUS)
DiscussionAcetylsalicylic acid is the most common antithrombotic given to patients with embolic strokes of undetermined source to reduce recurrence risk. This trial will determine whether anticoagulation with dabigatran is more effective than acetylsalicylic acid, and acceptably safe.
Source: International Journal of Stroke - September 30, 2015 Category: Neurology Authors: Hans‐Christoph Diener, J. Donald Easton, Christopher B. Granger, Lisa Cronin, Christine Duffy, Daniel Cotton, Martina Brueckmann, Ralph L. Sacco, Tags: Protocol Source Type: research

Design of Randomized, double ‐blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE‐SPECT ESUS)
International Journal of Stroke,Volume 10, Issue 8, Page 1309-1312, December 2015.
Source: International Journal of Stroke - September 30, 2015 Category: Neurology Source Type: research

Boehringer starts patient enrolment in dabigatran Phase III trial to prevent ESUS
Boehringer Ingelheim has started patient enrolment in the RE-SPECT ESUS Phase III trial designed to evaluate the efficacy and safety of dabigatran etexilate to prevent recurrent embolic stroke of undetermined source (ESUS).
Source: Drug Development Technology - December 17, 2014 Category: Pharmaceuticals Source Type: news